Obsidian Therapeutics raised $160.5M in a Series C financing led by Wellington Management to drive OBX-115 clinical development.

Apr 03, 2024•over 1 year ago

Amount Raised

$161 Million

Round Type

series c

CambridgeTherapeuticsHealth CareBiotechnology

Investors

Surveyor CapitalSamsara Bio CapitalTcgxRa Capital ManagementLogos CapitalDeep Track CapitalBristol Myers SquibbBlue Owl Healthcare OpportunitiesAtlas VentureWoodline Partners LpT. Rowe Price Associates, Inc.Rtw InvestmentsParadigm Bio CapitalNovo Holdings A/SJanus Henderson InvestorsForesite CapitalWellington Management

Description

Obsidian Therapeutics, Inc. announced the closure of a significantly oversubscribed $160.5 million Series C financing to advance its lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). The financing was led by top-tier syndicate of life science investors including Wellington Management.

Company Information

Company

Obsidian Therapeutics, Inc.

Location

1030 MASSACHUSETTS AVENUE

Cambridge, Massachusetts, United States

About

Obsidian Therapeutics, Inc. is a clinical biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.

Related People

4 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends